Mandy Jackson
Managing Editor, US Commercial News
Mandy reports on daily biopharma developments, writes feature stories and produces Scrip's Finance Watch column. She covers finance, start-ups, dealmaking, clinical trial results, quarterly earnings reports, commercial competition and corporate strategy.
Mandy regularly interviews everyone from big pharma CEOs to biotech start-up founders, enhancing her expertise on industry trends and market dynamics. She also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.
Latest From Mandy Jackson
Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation
CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.
SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors
SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply.
Finance Watch: Though Flush With Cash, Theseus Seeks Alternatives, Gets Two Quick Offers
Restructuring Edition: OrbiMed/Foresite and Concentra responded quickly after Theseus implemented a 72% workforce reduction and began a search for strategic alternatives despite having $225.4m in cash. REGENXBIO, Novavax and Lyell also revealed job cuts despite large cash stockpiles.
Money Is Flowing Into Biopharma But Funders Are Investing Selectively
Venture capital and public market fundraising have grown increasingly difficult since 2021, but while there are glimmers of hope, the rules for who can raise venture cash or launch an IPO have changed.
Finance Watch: Gilde Closes Sixth Venture Fund With €740m For Drugs, MedTech
Private Company Edition: The €740m ($806.5m) Gilde Healthcare Venture&Growth VI Fund will back companies in Europe and North America. Among recent financings, VectorY raised a €129m ($138m) series A round, EyeBio expanded its series A to $130m and MBrace raised an $85m series B.
BMS Grows Its Lung Cancer Portfolio With ‘Best-In-Class’ Augtyro Approval
Bristol Myers Squibb won US FDA approval for Augtyro (repotrectinib), from its $4.1bn Turning Point acquisition last year, in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).